AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20008701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 1346
Study 20008701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1346
Study 20008701 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch + lozenge
Number of subjects: 1346
Study 20008701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR + lozenge
Number of subjects: 1346
Study 16269248 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-fMRI
Number of subjects: 17
Study 16269248 — intervention group
Group type: COMPARATOR
Intervention: EEG dipole source localisation
Number of subjects: 17
Study 16269248 — intervention group
Group type: COMPARATOR
Intervention: Distributed source modelling
Number of subjects: 17
Study 14564941 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily foodlet containing multiple micronutrients
Number of subjects: 280
Study 14564941 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo foodlet containing no micronutrients
Number of subjects: 280
Study 14564941 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly foodlet containing multiple micronutrients (twice the dose of the daily foodlet) and placebo foodlets on other days
Number of subjects: 280
Study 14564941 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily foodlet containing only 10 mg of elemental iron
Number of subjects: 280
Study 10926646 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion (WI) for 3 hours
Number of subjects: 19
Study 10926646 — intervention group
Group type: COMPARATOR
Intervention: Seated nonimmersed for 5.5 hours (control)
Number of subjects: 19
Study 8880795 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 18
Study 8880795 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 18
Study 1357152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral interferon-alpha (50 U)
Number of subjects: 149
Study 1357152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral interferon-alpha (100 U)
Number of subjects: 149
Study 1357152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 4005103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol hydrochloride (50 mg twice daily)
Number of subjects: 29
Study 4005103 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (50 mg twice daily)
Number of subjects: 29
Study 4005103 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (twice daily)
Number of subjects: 29
Study 31144979 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.6 g protein/kg body weight
Number of subjects: 41
Study 31144979 — intervention group
Group type: COMPARATOR
Intervention: Diet with 1 g protein/kg body weight
Number of subjects: 41
Study 31144979 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 41
Study 29566934 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily 7.5mg tolvaptan
Number of subjects: 31
Study 29566934 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily 3.75mg tolvaptan
Number of subjects: 31
Study 26272586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (500 mg ceritinib)
Number of subjects: 2
Study 26272586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (500 mg ceritinib)
Number of subjects: 2
Study 26272586 — intervention group
Group type: EXPERIMENTAL
Intervention: Light snack (750 mg ceritinib)
Number of subjects: 2
Study 24819761 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% LF ointment
Number of subjects: 30
Study 24819761 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% LF ointment
Number of subjects: 30
Study 24819761 — intervention group
Group type: COMPARATOR
Intervention: Oral bovine LF 100 mg
Number of subjects: 30
Study 22476844 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative thromboprophylaxis with dalteparin (starting 12 hours before surgery)
Number of subjects: 80
Study 22476844 — intervention group
Group type: COMPARATOR
Intervention: Postoperative thromboprophylaxis with dalteparin (starting 6 hours after surgery)
Number of subjects: 80
Study 20451185 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mL of air pushed into the catheter after embryo transfer
Number of subjects: 55
Study 20451185 — intervention group
Group type: COMPARATOR
Intervention: Standard embryo transfer technique (without air)
Number of subjects: 55
Study 18408261 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath ammonia measurement using a QCM-NH3 sensor
Number of subjects: 0
Study 15765988 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mg dose of bupivacaine with 20 microg of fentanyl
Number of subjects: 42
Study 15765988 — intervention group
Group type: COMPARATOR
Intervention: 6.5 mg dose of bupivacaine with 20 microg of fentanyl
Number of subjects: 42
Study 11801426 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 66
Study 11801426 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 66
Study 15374060 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (6.25 mg twice daily for the first week, increased to 12.5 mg during weeks 2-4, and to 25 mg from weeks 5-12)
Number of subjects: 40
Study 15374060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7579469 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered blood products
Number of subjects: 502
Study 7579469 — intervention group
Group type: COMPARATOR
Intervention: CMV-seronegative blood products
Number of subjects: 502
Study 1668100 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol) rich in linoleic and gamma-linolenic acids for 8 months
Number of subjects: 39
Study 1668100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7139977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 12
Study 7139977 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dihydralazine
Number of subjects: 12
Study 30753625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) during pregnancy and postpartum plus LNSs for infants from 6 to 18 months
Number of subjects: 1320
Study 30753625 — intervention group
Group type: COMPARATOR
Intervention: Non-LNS group (iron and folic acid during pregnancy and 200 mg Ca for 6 months postpartum; multiple micronutrients during pregnancy and postpartum)
Number of subjects: 1320
Study 27016157 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abutment placed at the time of implant placement
Number of subjects: 40
Study 27016157 — intervention group
Group type: COMPARATOR
Intervention: Definitive abutment placed 6-12 weeks later (control group)
Number of subjects: 40
Study 27016157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and test)
Number of subjects: 40
Study 26174581 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index milk (GI = 23)
Number of subjects: 56
Study 26174581 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic index milk (GI = 65)
Number of subjects: 56
Study 23907700 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (75 or 150 mg QD) with Pegylated interferon and ribavirin
Number of subjects: 0
Study 23907700 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Pegylated interferon and ribavirin
Number of subjects: 0
Study 21409538 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksheet provided
Number of subjects: 241
Study 21409538 — intervention group
Group type: COMPARATOR
Intervention: No worksheet provided (Control)
Number of subjects: 241
Study 18987053 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 1 mg ml(‐1) plus dexmedetomidine 5 microg ml(‐1) (Group D)
Number of subjects: 100
Study 18987053 — intervention group
Group type: COMPARATOR
Intervention: morphine 1 mg ml(‐1) alone (Group M)
Number of subjects: 100
Study 17606247 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from family and friends for healthy eating
Number of subjects: 1942
Study 17606247 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from friends
Number of subjects: 1942
Study 12653820 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP clinic intervention
Number of subjects: 470
Study 12653820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 470
Study 10506237 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (physicians received written feedback about compliance scores)
Number of subjects: 0
Study 10506237 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback and incentive group (physicians received feedback and a financial bonus when compliance criteria were met)
Number of subjects: 0
Study 10506237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8616760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 184
Study 1751561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous digital subtraction angiography (DSA)
Number of subjects: 36
Study 1751561 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial digital subtraction angiography (DSA)
Number of subjects: 36
Study 7332740 — intervention group
Group type: EXPERIMENTAL
Intervention: SC8109
Number of subjects: 6
Study 7332740 — intervention group
Group type: COMPARATOR
Intervention: spironolactone
Number of subjects: 6
Study 31250182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program (8-week, bi-weekly education and exercise program)
Number of subjects: 188
Study 31250182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 188
Study 30406378 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (nurse's online guidance through a mobile medical App and regular offline clinical treatment)
Number of subjects: 124
Study 30406378 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 124
Study 28292319 — intervention group
Group type: EXPERIMENTAL
Intervention: KLH
Number of subjects: 553
Study 28292319 — intervention group
Group type: COMPARATOR
Intervention: MM
Number of subjects: 553
Study 25061029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) intervention, consisting of an exercise program with ten sessions, two times a week for one hour each.
Number of subjects: 37
Study 25061029 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with observation only, no intervention.
Number of subjects: 37
Study 22708917 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless implants
Number of subjects: 20
Study 22708917 — intervention group
Group type: COMPARATOR
Intervention: Flapped implants
Number of subjects: 20
Study 22093849 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1000 mg/d for 3 days plus bronchoalveolar lavage
Number of subjects: 21
Study 22093849 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone 1000 mg/d for 3 days
Number of subjects: 21
Study 18661135 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated parotid glands
Number of subjects: 19
Study 18661135 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated parotid glands
Number of subjects: 19
Study 16464717 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT ERNA
Number of subjects: 27
Study 16464717 — intervention group
Group type: COMPARATOR
Intervention: EBCT
Number of subjects: 27
Study 14996518 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (initially 2 mg once daily, increased by 1 mg every 2 weeks until FPG <6.7 mmol/L, maintained for 24 weeks)
Number of subjects: 14
Study 14996518 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 14
Study 14996518 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance tests (OGTTs) conducted in the control group
Number of subjects: 14
Study 10364997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 11
Study 10364997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 11
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP mode A
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP mode B
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP mode C
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP mode D
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP mode E
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-discharge EP
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-op ATP
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary ICD shocks
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 82
Study 7863712 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up
Number of subjects: 82
Study 1911428 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 1911428 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (non-responders)
Number of subjects: 0
Study 1911428 — intervention group
Group type: COMPARATOR
Intervention: Patients with respiratory failure
Number of subjects: 0
Study 1911428 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone concentrations
Number of subjects: 0
Study 7240597 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium metabisulfite (K2S2O5) oral challenges
Number of subjects: 4
Study 7240597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30600961 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral thigh flap transfer
Number of subjects: 80
Study 30600961 — intervention group
Group type: COMPARATOR
Intervention: Forearm flap transfer
Number of subjects: 80
Study 29099947 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1‐84) (n = 83)
Number of subjects: 122
Study 29099947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 39)
Number of subjects: 122
Study 27183138 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 102
Study 27183138 — intervention group
Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 102
Study 24668102 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 136
Study 24668102 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic surveillance
Number of subjects: 136
Study 22776430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (n = 57)
Number of subjects: 116
Study 22776430 — intervention group
Group type: COMPARATOR
Intervention: CNI (n = 59)
Number of subjects: 116
Study 20214065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral administration of Propranolol
Number of subjects: 60
Study 20214065 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Propranolol only
Number of subjects: 60
Study 16580027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision alone
Number of subjects: 0
Study 16580027 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch alone
Number of subjects: 0
Study 16580027 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch and vision together
Number of subjects: 0
Study 16580027 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal (vision and touch)
Number of subjects: 0
Study 16239762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg twice daily
Number of subjects: 8
Study 16239762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11851956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) of diethylcarbamazine (DEC) plus ivermectin (IVR)
Number of subjects: 7
Study 11851956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) of diethylcarbamazine (DEC) plus ivermectin (IVR) with vector control
Number of subjects: 7
Study 11851956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11851956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector control
Number of subjects: 7
Study 10190770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 ratio of concentric to eccentric contractions
Number of subjects: 2
Study 10190770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:2 ratio of concentric to eccentric contractions
Number of subjects: 2
Study 7635603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation during early childhood
Number of subjects: 460
Study 31571392 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (LSS) to predict tacrolimus AUC0-12h
Number of subjects: 56
Study 31571392 — intervention group
Group type: COMPARATOR
Intervention: Prograf® or non-innovator tacrolimus formulations
Number of subjects: 56
Study 28398692 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days intravenous antibiotics
Number of subjects: 132
Study 28398692 — intervention group
Group type: COMPARATOR
Intervention: 10 days intravenous antibiotics
Number of subjects: 132
Study 25567659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 150
Study 25567659 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 23296434 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures of infant neurodevelopment
Number of subjects: 193
Study 23296434 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at baseline
Number of subjects: 193
Study 23296434 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported functional abilities and hemoglobin concentration
Number of subjects: 193
Study 22111658 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 μg/kg
Number of subjects: 90
Study 22111658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 90
Study 19393046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (DVD and written workbook)
Number of subjects: 1206
Study 19393046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (DVD and written workbook) + follow up education training visits by a health professional
Number of subjects: 1206
Study 19393046 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1206
Study 17644072 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (60 mg)
Number of subjects: 22
Study 17644072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14722176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 micro g kg(‐1)
Number of subjects: 64
Study 14722176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 micro g kg(‐1)
Number of subjects: 64
Study 14722176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micro g kg(‐1)
Number of subjects: 64
Study 14722176 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 64
Study 14722176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 to 1 micro g kg(‐1))
Number of subjects: 64
Study 11712623 — intervention group
Group type: EXPERIMENTAL
Intervention: Netamiftide (18 mg/patient per day) for 10 days
Number of subjects: 55
Study 11712623 — intervention group
Group type: EXPERIMENTAL
Intervention: Netamiftide (18 mg/patient per day) for 5 days followed by 5 days of placebo
Number of subjects: 55
Study 11712623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 55
Study 9042130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill form of cholestyramine (8 gm/day)
Number of subjects: 40
Study 9042130 — intervention group
Group type: COMPARATOR
Intervention: Powder form of cholestyramine (8 gm/day)
Number of subjects: 40
Study 9042130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of cholestyramine
Number of subjects: 40
Study 8162917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low impact dance
Number of subjects: 10
Study 8162917 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact dance with arm work
Number of subjects: 10
Study 8162917 — intervention group
Group type: COMPARATOR
Intervention: Dance (various styles)
Number of subjects: 10
Study 8162917 — intervention group
Group type: COMPARATOR
Intervention: Stepping (traditional step test)
Number of subjects: 10
Study 2835964 — intervention group
Group type: COMPARATOR
Intervention: E + P (Enalapril + Placebo)
Number of subjects: 200
Study 2835964 — intervention group
Group type: EXPERIMENTAL
Intervention: E + H 12.5 (Enalapril + Hydrochlorothiazide 12.5 mg/day)
Number of subjects: 200
Study 2835964 — intervention group
Group type: EXPERIMENTAL
Intervention: E + H 25 (Enalapril + Hydrochlorothiazide 25 mg/day)
Number of subjects: 200
Study 31913422 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressing stoma (DS)
Number of subjects: 3153
Study 31913422 — intervention group
Group type: COMPARATOR
Intervention: Self‐expandable metal stent (SEMS)
Number of subjects: 3153
Study 30067928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of rifampin
Number of subjects: 844
Study 30067928 — intervention group
Group type: COMPARATOR
Intervention: 9 months of isoniazid
Number of subjects: 844
Study 26967547 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute patterned electrical neuromuscular stimulation (PENS) treatment
Number of subjects: 22
Study 26967547 — intervention group
Group type: COMPARATOR
Intervention: 15-minute 1-mA subsensory (sham) treatment
Number of subjects: 22
Study 25645567 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 0
Study 23870798 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + memantine (5 mg/day)
Number of subjects: 135
Study 23870798 — intervention group
Group type: COMPARATOR
Intervention: VPA + placebo
Number of subjects: 135
Study 20103449 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System
Number of subjects: 23
Study 20103449 — intervention group
Group type: COMPARATOR
Intervention: Copper T 380A
Number of subjects: 23
Study 18855244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine
Number of subjects: 6
Study 18855244 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day)
Number of subjects: 6